Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody.

Front Pharmacol · 2025 · PMC12209307 · PMID 40599804

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

As shown in Figures 6A–F , the levels of SRC phosphorylation, JUNB, FOSB and PD-L1 all presented an increasing trend in KRAS G12C -mutant NSCLC cells overexpressing SRC.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.